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1. Introduction
The human body consists of two major compartments, a
cellular and an extracellular compartment. Most types of in-
jury confer damage to both of these compartments, and the
following healing process therefore involves regeneration of
both the cellular and extracellular mass, the extracellular ma-
trix (ECM). Irrespective of the a¡ected tissue, this wound
healing process follows a conserved sequence of events, in-
cluding initiation and execution of (i) the coagulation cascade,
(ii) an in£ammatory response (associated with angiogenesis,
formation of granulation tissue, and reepithelialization of de-
nuded areas), and (iii) a ¢broproliferative response (including
proliferation of mesenchymal cells and increased synthesis of
ECM) [1]. In normal wound healing, a network of negative
feedback mechanisms activated after successful healing is re-
sponsible for the proper termination of the proliferative and
¢brotic processes, thus restoring tissue integrity. If these feed-
back mechanisms fail to operate, however, continuous ECM
secretion and deposition will lead to perturbation of normal
tissue architecture and ‘endless healing’, with the eventual
development of tissue ¢brosis. Alternatively, such ‘endless
healing’ may also be due to repeated injuries leading to con-
tinuous activation of the ¢broproliferative response. Although
the exact molecular mechanisms leading to such unregulated
and continuous deposition of ECM molecules remain enig-
matic, accumulating evidence from multiple in vivo and in
vitro observations suggests that transforming growth factor
(TGF)-L is a key soluble mediator in the development of ¢-
brosis (for a review, see [2]).
2. The TGF-L system
TGF-L represents the prototypic member of a large family
of polypeptide growth factors, which, due to ubiquitous ex-
pression of its cell surface receptors, exerts multiple biological
e¡ects on most cell types. TGF-L plays an important and non-
redundant role in embryonic development and cellular di¡er-
entiation, regulates cellular proliferation, induces synthesis of
ECM proteins, and modulates the immune response, thus
identifying it as a key regulator of both cellular and extracel-
lular homeostasis. Interestingly, TGF-L can lead to com-
pletely opposite biological e¡ects, depending on the cell type
investigated, e.g. stimulation of proliferation in ¢broblasts vs.
inhibition of proliferation in epithelial cells. The cloning and
characterization of three membrane-bound TGF-L receptors,
designated TLRI, TLRII, and TLRIII (betaglycan) repre-
sented a milestone in the ¢eld of signal transduction; TLRI
and TLRII were the ¢rst membrane-bound receptors exhibit-
ing intrinsic serine^threonine kinase activity [3,4]. This discov-
ery thus introduced a completely novel intracellular signaling
mechanism activated by extracellular ligands, apart from the
then well-known tyrosine kinase receptor system.
Many of the biological e¡ects induced by TGF-L are asso-
ciated with activation of diverse transcription factor systems,
including activating protein-1 (AP-1) and mitogen-activated
protein kinase (MAPK) family members. Beginning in 1995,
the cloning of Smad molecules led to the discovery and des-
ignation of a novel and previously unknown class of tran-
scription factors, which directly interacted with the signal
transducing receptor isotype TLRI. To date, sequence and
functional analysis of eight Smad isoforms has led to their
classi¢cation into three subgroups; (i) receptor-regulated
Smads, which directly function as substrate molecules for
phosphorylated type I receptors (Smad1, 5, 8 for BMP ligands
and Smad2 and 3 for TGF-L ligands), (ii) the common
Smad4, which is thought to be the binding partner for all
receptor-regulated Smads, facilitating their translocation into
the nucleus, and (iii) inhibitory Smads (Smad6 and 7), which
inhibit the association of receptor-regulated Smads with the
type I receptors and thereby antagonize TGF-L-induced ef-
fects [5,6].
In the current model of TGF-L signal transduction, biolog-
ical e¡ects of TGF-L are induced after binding of active TGF-
L to the ligand binding receptor isotype, TLRII. This leads to
formation and stabilization of a heterotetrameric complex of
TLRI and TLRII, followed by transphosphorylation of TLRI
by the constitutively active TLRII kinase in its intracellular
juxtamembrane region rich in glycine and serine residues,
termed the GS domain. Subsequent phosphorylation of the
receptor-associated cytoplasmic e¡ector molecules Smad2 or
Smad3 by TLRI then leads to heterooligomerization of phos-
phorylated Smad2/3 with the common Smad4, and modula-
tion of gene transcription in the nucleus (Fig. 1) [6,7]. TLRIII
(betaglycan) is a widely expressed heparan- and chondroitin
sulfate proteoglycan that binds TGF-L with high a⁄nity
through its protein core. Betaglycan facilitates ligand binding
to TLRII, but recent reports have indicated that it may play a
far more complex role, exhibiting positive and/or negative
e¡ects on TGF-L signaling, depending on the cell type ([8,9],
and O. Eickelberg and R.G. Wells, submitted).
3. TGF-L and ¢brosis : mechanisms and hypotheses
The pathophysiology of tissue ¢brosis is characterized by
two related events, (i) transdi¡erentiation of ¢broblasts into
0014-5793 / 01 / $20.00 ß 2001 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 8 7 5 - 7
*Fax: (1)-203-785 3348.
E-mail address: oliver.eickelberg@yale.edu (O. Eickelberg).
FEBS 25273 26-9-01 Cyaan Magenta Geel Zwart
FEBS 25273 FEBS Letters 506 (2001) 11^14
‘activated’ myo¢broblasts, and (ii) enhanced synthesis and
secretion of ECM molecules by these cells. The pathological
hallmark of ¢brosis is the accumulation of excess amounts of
ECM in the a¡ected tissue, due to both quantitative and
qualitative changes in ECM composition [1]. TGF-L has
been shown to play a pivotal role in the initiation and degree
of ¢brosis in a variety of organ systems, including the lung,
liver, and kidney, and attempts to inhibit or antagonize TGF-
L activity have led to promising results in downregulating or
reversing tissue ¢brosis [2].
In this issue of FEBS letters, Ricupero et al. describe anti-
¢brotic e¡ects of a dietary £avonoid, apigenin, in a cell cul-
ture model using human embryonic lung ¢broblasts [10]. Fla-
vonoids represent a widespread class of natural compounds
with potent antioxidant, antiproliferative, and anti¢brotic ef-
fects. To date, more than 4000 di¡erent £avonoid substances
have been isolated and identi¢ed from a multitude of plant
species. In the plant kingdom, £avonoids protect against UV
light and pathogenic microorganisms, and some of the con-
spicuous colors seen in plants are due to the chemical nature
of £avonoids [11]. For centuries, £avonoids in herbal extracts
have been used in Chinese and Japanese medicine, particularly
in patients with chronic hepatitis or cirrhosis. In this issue’s
study, Ricupero et al. demonstrate that apigenin decreases
proliferation and collagen synthesis of lung ¢broblasts in
a time- and dose-dependent manner. Apigenin acts as a
TGF-L inhibitor, attenuating TGF-L-induced collagen and
K-smooth muscle actin (K-SMA) mRNA synthesis. This inhi-
bition seemed pathway speci¢c, since TGF-L-induced connec-
tive tissue growth factor (CTGF) expression was una¡ected
by apigenin [10]. The study therefore suggests that TGF-L
simultaneously activates at least two di¡erent and indepen-
dent signal transduction mechanisms in lung ¢broblasts, one
leading to increased expression of collagen and K-SMA, the
other leading to increased CTGF expression. Since TGF-L-
induced CTGF expression is reported to be Smad3-and
Smad4-dependent [12], these results suggest that apigenin
may speci¢cally interfere with Smad2, but not Smad3 activity.
As such, apigenin may represent a useful compound to further
dissect TGF-L-induced signaling pathways, as well as a mod-
ulator of the ¢brotic response, especially in light of its non-
toxic and non-mutagenic nature.
As aforementioned, Smad molecules are directly phosphor-
ylated by TLRI, and represent the immediate substrate mole-
cules of activated TGF-L receptors. However, TGF-L is also
known to activate other signal transduction pathways, includ-
ing the MAPK or AP-1 pathways, and this may occur inde-
pendent of Smad phosphorylation and activation. Theoreti-
cally, the preferential activation of one TGF-L signaling
pathway vs. another (e.g. Smad2 vs. Smad3, or AP-1 vs.
Smads) through biochemical or pharmaceutical modulation
can therefore potentially modify the cellular response to
TGF-L.
A recent article by Reisdorf et al., suggested such mecha-
nisms during the development of skin ¢brosis [13]. In their
study, the authors used a pig model of Q-irradiation-induced
skin ¢brosis, which is characterized by excess proliferation of
¢broblasts, transdi¡erentiation of ¢broblasts into activated
Fig. 1. TGF-L signal transduction. TGF-L signal transduction is initiated by binding of TGF-L ligand to TLRII. TLRI is then recruited into
the receptor complex, followed by stabilization of TLRI/TLRII heterotetrameric complexes, and phosphorylation of the kinase domain of TLRI
by the constitutively autophosphorylated TLRII kinase. Phosphorylated TLRI then recruits and phosphorylates Smad2/3 molecules, which,
upon dissociation from TLRI, form dimers with Smad4. Smad2/3-Smad4 heterodimers translocate to the nucleus where they recruit cofactors in
order to activate or repress gene transcription. Regulation of TGF-L activity can occur at multiple levels, including: (1) availability of active li-
gand through TGF-L binding proteins or soluble receptors, (2) formation of active receptor complexes through interaction with betaglycan, en-
doglin, or the pseudoreceptor BAMBI, (3) Smad2/3 phosphorylation through competition for TLRI by the inhibitory Smads 7 and 8, (4) for-
mation of Smad2/3-Smad4 dimers through mutations in Smad4, and (5) activity and recruitment of transcriptional activators or repressors.
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myo¢broblasts, and TGF-L-induced increased ECM deposi-
tion in irradiated skin areas. Reisdorf et al. isolated primary
skin ¢broblasts and myo¢broblasts from non-irradiated, con-
trol areas and ¢brotic areas, respectively, and assessed their
responses to TGF-L, hypothesizing that molecular events trig-
gered during the irradiation process altered TGF-L respon-
siveness of these cells. Both cell populations consistently re-
vealed similar expression levels of TLRI, TLRII, Smad2, 3,
and 4. Myo¢broblasts, however, exhibited a signi¢cant de-
crease in TGF-L-dependent growth inhibition, reporter gene
expression, and Smad3/4 DNA binding activity. This decrease
in TGF-L-induced responses was independent of di¡erential
expression of the inhibitory Smad7, but coincided with re-
duced nuclear translocation of Smad3. Thus, the authors
argue that a relative loss of Smad3 activity leads to a decrease
in proliferative and transcriptional responses to TGF-L,
whereas ¢brotic mechanisms remain una¡ected by Smad3 dys-
function [13].
Such an uncoupling of the pro¢brotic and antiproliferative
responses of TGF-L due to altered activity of Smad isoforms
has been proposed earlier by Anita Roberts’s group. Mice
lacking Smad3 exhibit accelerated cutaneous wound healing,
and keratinocytes derived from Smad3 null mice demonstrate
a reduced sensitivity to TGF-L-mediated growth inhibition.
Matrix deposition in incisional wounds, however, occurred
at similar levels in wild-type and Smad3 null mice, providing
further evidence that Smad3 activity is required for prolifer-
ative, but not matrix e¡ects in response to TGF-L [14]. In
contrast, analysis of CCl4-induced liver ¢brosis in Smad3
null mice suggested that Smad3 seems to be required for max-
imal collagen type I induction during ¢brosis [15], although
this may include e¡ects other than merely TGF-L-dependent
mechanisms. Analyses of mouse embryonic ¢broblasts derived
from Smad2 and Smad3 null animals has suggested that c-fos,
Smad7, and TGF-L1 induction by TGF-L is Smad3-depen-
dent, whereas MMP-2 expression is Smad2-dependent (Table
1). Fibronectin induction was independent of either Smad,
whereas growth inhibition in a variety of cell types was
Smad2/3-dependent [16].
Taken together, these studies have conclusively suggested
that it is possible to alter a particular response to TGF-L
without a¡ecting others by selective inactivation or overex-
pression of a particular signaling molecule within the TGF-
L pathway. In addition to the di¡erential contribution of
Smad2 and Smad3, the speci¢c outcome of a TGF-L-initiated
cellular response seems also dependent on the simultaneous
activation of Smad-independent signaling pathways, such as
the MAPK or AP-1 pathways (Fig. 2, Table 1). The speci¢c
Table 1
Biological e¡ects induced by TGF-L, which are dependent on speci¢c signaling compounds within the TGF-L system
Signaling intermediate Required for expression of, mediates
Smad2 PAI-1 [16], MMP-2 [16], Smad4 [19,20], TGF-L [19,20], Mix.2 [21,22], antiproliferative e¡ects of TGF-L [16]
Smad3 CTGF [12], TGF-L [14,16], Collagen type I [15], c-fos [16], Smad7 [16], PAI-1 [16,25], p15 [23], Mix.2 [24],
antiproliferative e¡ects of TGF-L [13^16,23,25,26]
AP-1/JunD/MAPK Collagen deposition [18], Fibronectin [27], IL-6 [28], PAI-1 [29], TGF-L1 [30,31]
Fig. 2. A proposed model for the contribution of di¡erent TGF-L signaling pathways to the cellular response. In most cells, several signal
transduction pathways, including the MAPK and AP-1 families are expressed and active along with the Smad pathway. The cellular response
to TGF-L therefore depends on the ¢ne-tuned activation of coexisting pathways and crosstalk between pathways, implying that modulation of
one pathway vs. another will a¡ect the outcome of the cellular response to TGF-L.
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contribution of each of these pathways, as well as crosstalk
between pathways, ultimately determines the outcome of a
given cell’s response to TGF-L. This entails that the speci¢c
availability and activation of such pathways determines
whether TGF-L treatment will result in an antiproliferative
response or a ¢brotic response, as seen in the case of lung
¢brosis.
Whereas Smads have been implicated in the pathophysiol-
ogy of lung ¢brosis [17], stimulation of collagen and ECM
deposition by TGF-L is mediated by JunD, a member of the
AP-1 family of transcription factors [18]. It remains to be
analyzed whether, in patients with lung ¢brosis, the preferen-
tial activation of one signal transduction pathway, such as the
AP-1 pathway, has facilitated the development of ¢brosis.
Hypothetically, the preferential activation of one pathway
(such as AP-1) vs. the inactivation of another (such as Smads)
may shift the biological response evoked by TGF-L to a ¢-
brotic phenotype, whereas this response in an environment of
relatively abundant Smads could lead to a predominantly
antiproliferative response, and apigenin may present as a use-
ful tool to investigate such mechanisms [10]. As such, further
clari¢cation of the di¡erential contributions of TGF-L-in-
duced signaling systems to the cellular response over the
next years will more than likely enrich our understanding of
the tissue speci¢c e¡ects of TGF-L, and may lead to the dis-
covery of novel therapeutic options for the treatment of ¢-
brotic diseases.
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